 <h1>Arcalyst Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>rilonacept</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about rilonacept. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Arcalyst.</p><h2>In Summary</h2><p><b>Common side effects of Arcalyst include:</b> upper respiratory tract infection and injection site reaction.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to rilonacept: subcutaneous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, rilonacept (the active ingredient contained in Arcalyst) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking rilonacept:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at site</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty in breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloody or black, tarry stools</li>
<li>constipation</li>
<li>cough producing mucus</li>
<li>lower back or side pain</li>
<li>pain or tenderness around eyes and cheekbones</li>
<li>painful or difficult urination</li>
<li>severe stomach pain</li>
<li>shortness of breath or troubled breathing</li>
<li>tenderness</li>
<li>tightness of chest or wheezing</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of rilonacept may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Stomach discomfort</li>
</ul><p>
<!-- end subcutaneous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rilonacept: subcutaneous powder for injection</i></p><h3>Local</h3><p>In patients with Cryopyrin-Associated Periodic Syndromes (CAPS), the most common and consistently reported adverse event associated with rilonacept (the active ingredient contained in Arcalyst) was injection-site reaction (ISR).  The ISRs included erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, and hemorrhage.  Most injection-site reactions lasted for one to two days.  No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Injection site reactions (e.g., erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, hemorrhage) (48%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (34%)<sup>[Ref]</sup></p><p>One subject receiving rilonacept for an unapproved indication developed an infection in his olecranon bursa with Mycobacterium intracellulare.  The patient was on chronic glucocorticoid treatment.  The infection occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria.  The patient recovered after the administration of the appropriate antimicrobial therapy.</p>
<p></p>
<p>A patient treated for another unapproved indication developed bronchitis/sinusitis, which resulted in hospitalization.</p>
<p></p>
<p>One patient died in an open-label study of CAPS from Streptococcus pneumoniae meningitis.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (26%)</p>
<p><b>Common</b> (1% to 10%): Sinusitis, cough<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Hypoesthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, stomach disorder<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The patient did not experience any infection associated with the neutropenia.</p>
<p></p>
<p>Physicians should monitor the lipid profiles of their patients (for example after 2 to 3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Neutropenia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Increased mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (in patients with CAPS)<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reaction is injection-site reaction (ISR).  The next most commonly reported adverse reaction is upper respiratory infection.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Arcalyst (rilonacept)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Arcalyst &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Familial Cold Autoinflammatory Syndrome</li>
<li>Cryopyrin-Associated Periodic Syndromes</li>
<li>Muckle Wells Syndrome</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rilonacept: subcutaneous powder for injection</i></p><h3>Local</h3><p>In patients with Cryopyrin-Associated Periodic Syndromes (CAPS), the most common and consistently reported adverse event associated with rilonacept (the active ingredient contained in Arcalyst) was injection-site reaction (ISR).  The ISRs included erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, and hemorrhage.  Most injection-site reactions lasted for one to two days.  No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Injection site reactions (e.g., erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, hemorrhage) (48%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (34%)<sup>[Ref]</sup></p><p>One subject receiving rilonacept for an unapproved indication developed an infection in his olecranon bursa with Mycobacterium intracellulare.  The patient was on chronic glucocorticoid treatment.  The infection occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria.  The patient recovered after the administration of the appropriate antimicrobial therapy.</p><p></p><p>A patient treated for another unapproved indication developed bronchitis/sinusitis, which resulted in hospitalization.</p><p></p><p>One patient died in an open-label study of CAPS from Streptococcus pneumoniae meningitis.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (26%)</p><p><b>Common</b> (1% to 10%): Sinusitis, cough<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Hypoesthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, stomach disorder<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The patient did not experience any infection associated with the neutropenia.</p><p></p><p>Physicians should monitor the lipid profiles of their patients (for example after 2 to 3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Neutropenia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Increased mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (in patients with CAPS)<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reaction is injection-site reaction (ISR).  The next most commonly reported adverse reaction is upper respiratory infection.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p><h2>More about Arcalyst (rilonacept)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Arcalyst &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Familial Cold Autoinflammatory Syndrome</li>
<li>Cryopyrin-Associated Periodic Syndromes</li>
<li>Muckle Wells Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>